Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

Business Wire 13 days ago

Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall

Business Wire September 12, 2022

bluebird bio Announces September Investor Events

Business Wire August 29, 2022

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire August 4, 2022

FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire June 10, 2022

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Business Wire June 9, 2022

bluebird bio stock trading halted today June 9th and tomorrow June 10th

Business Wire June 9, 2022

bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting

Business Wire June 7, 2022

bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire May 9, 2022

bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US

Business Wire April 5, 2022

bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update

Business Wire March 4, 2022

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

GlobeNewswire January 26, 2022

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

Business Wire January 18, 2022

bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 11, 2022

bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2022

bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

Business Wire December 20, 2021

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

Business Wire December 17, 2021

New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM

Business Wire December 12, 2021